Bradley to buy Bioglan in $183M deal

Bradley Pharmaceuticals is to acquire fellow US firm Bioglan Pharmaceuticals from its present owner, Quintiles Transnational, for a consideration of $183 million, plus direct cost for transferred inventory.

By acquiring Bioglan, Bradley says it will enter valuable areas of dermatology in which it previously did not have a product presence, including the actinic keratosis sector which has annual sales of around $70 million, the oral acne antibiotic segment which is valued at around $220 million a year and the fast-growing market for direct sales to dermatologists for in-office procedures.

Bradley notes that Bioglan has experienced "dramatic growth," generating sales of around $55 million for the 12 months ended April 30. Its product portfolio includes Solaraze (diclofenac sodium), Adoxa (doxycycline), Zonalon (doxepin) and Tx Systems, a line of advanced topical treatments used during in-office procedures.